Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview

Life Sciences, Journal Year: 2023, Volume and Issue: 334, P. 122257 - 122257

Published: Nov. 8, 2023

Language: Английский

---

Oxidative Stress and Age-Related Tumors

Antioxidants, Journal Year: 2024, Volume and Issue: 13(9), P. 1109 - 1109

Published: Sept. 13, 2024

Oxidative stress is the result of imbalance between reactive oxygen and nitrogen species (RONS), which are produced by several endogenous exogenous processes, antioxidant defenses consisting molecules that protect biological systems from free radical toxicity. a major factor in aging process, contributing to accumulation cellular damage over time. biomolecules, leads DNA alterations, lipid peroxidation, protein oxidation, mitochondrial dysfunction resulting senescence, immune system tissue dysfunctions, increased susceptibility age-related pathologies, such as inflammatory disorders, cardiovascular neurodegenerative diseases, diabetes, cancer. stress-driven mutations, or methylation histone modification, alter gene expression, key determinants tumor initiation, angiogenesis, metastasis, therapy resistance. Accumulation genetic epigenetic damage, oxidative contributes, eventually unrestrained cell proliferation, inhibition differentiation, evasion death, providing favorable conditions for tumorigenesis. Colorectal, breast, lung, prostate, skin cancers most frequent aging-associated malignancies, implicated their pathogenesis behavior. Our aim shed light on molecular mechanisms link stress, aging, cancers, highlighting impact both RONS antioxidants, provided diet exercise, immunity, development an antitumor response. The dual role ROS physiological regulators signaling responsible well its use anti-tumor therapeutic purposes, will also be discussed. Managing crucial promoting healthy reducing risk tumors.

Language: Английский

---

Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson’s Disease

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(3), P. 839 - 839

Published: March 3, 2023

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by accumulation of protein deposits in dopaminergic neurons. These are primarily composed aggregated forms α-Synuclein (α-Syn). Despite extensive research on this only symptomatic treatments currently available. However, recent years, several compounds, mainly an aromatic character, targeting α-Syn self-assembly and amyloid formation have been identified. discovered different approaches, chemically diverse exhibit a plethora mechanisms action. This work aims to provide historical overview physiopathology molecular aspects associated with disease current trends small compound development target aggregation. Although these molecules still under development, they constitute important step toward discovering effective anti-aggregational therapies for disease.

Language: Английский

---

Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature

Biomedicines, Journal Year: 2024, Volume and Issue: 12(3), P. 549 - 549

Published: Feb. 29, 2024

In light of the unsuccessful traditional therapies for Parkinson's disease (PD) overmany years, there is an unmet need development novel to alleviate symptoms PD retardation or halt progression itself. This systematic review aims critically update some most promising treatments including gene therapy, cell-based therapies, targeted drug delivery, and neuroprotective agents, focusing on their challenges, limitations future directions in research. Gene therapy encouraging, with AAV-based approaches targeting neurotrophic factors, dopamine production, neuronal circuits animal clinical trials. A approach delivery involves use nanotechnology create vehicles that can traverse blood-brain barrier deliver medications specifically regions brain affected by PD. Neuroprotective agents are compounds have ability protect neurons from degeneration death, they hold great promise evolution disease-modifying Magnetic field a non-invasive method promotes neural plasticity The establishment standardized protocols human studies, safety, ethical considerations, cost-effectiveness major challenges research therapies. represents path toward effective personalized

Language: Английский

---

Glial Cell Reprogramming in Ischemic Stroke: A Review of Recent Advancements and Translational Challenges

Translational Stroke Research, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 4, 2025

Language: Английский

---

CRISPR innovations in tissue engineering and gene editing

Life Sciences, Journal Year: 2024, Volume and Issue: unknown, P. 123120 - 123120

Published: Oct. 1, 2024

Language: Английский

---

NIR‐Assisted MgO‐Based Polydopamine Nanoparticles for Targeted Treatment of Parkinson's Disease through the Blood–Brain Barrier

Advanced Healthcare Materials, Journal Year: 2022, Volume and Issue: 11(23)

Published: Sept. 25, 2022

The blood-brain barrier (BBB) is a major limiting factor that prevents the treatment of Parkinson's disease (PD). In present study, MgOp@PPLP nanoparticles are explored by using MgO as substrate, polydopamine shell, wrapping anti-SNCA plasmid inside, and modifying polyethylene glycol, lactoferrin, puerarin on surface to improve hydrophilicity, brain targeting antioxidant properties particles, respectively. exhibits superior near-infrared radiation (NIR) response. Under guidance photothermal effect, these particles capable penetrating BBB be taken up neuronal cells exert gene therapy therapy. both in vivo vitro models PD, good neuroprotective effects. Therefore, combined with noninvasive NIR radiation, nanoplatform biocompatibility becomes an ideal material combat neurodegenerative diseases.

Language: Английский

---

Neural stem cells for Parkinson’s disease management: Challenges, nanobased support, and prospects

World Journal of Stem Cells, Journal Year: 2023, Volume and Issue: 15(7), P. 687 - 700

Published: July 24, 2023

Parkinson's disease (PD), characterized by loss of nigrostriatal dopaminergic neurons, is one the most predominant neurodegenerative diseases affecting elderly population worldwide. The concept stem cell therapy in managing has evolved over years and recently rapidly progressed. Neural cells (NSCs) have a few key features, including self-renewal, proliferation, multipotency, which make them promising agent targeting neurodegeneration. It generally agreed that challenges for NSC-based are present at every stage transplantation process, preoperative preparation quality control, perioperative procedures, postoperative graft preservation, adherence, overall success. In this review, we provided comprehensive, careful, critical discussion experimental clinical data alongside pros cons PD. Given state-of-the-art accomplishments therapy, gene nanotechnology, shed light on perspective complementing advantages each process developing nano-stem currently research hotspot. Although various obstacles remain, holds promise to cure PD, however, continuous improvement development from laboratory experiments application necessary.

Language: Английский

---

Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(21)

Published: Jan. 25, 2024

Parkinson's disease (PD) is one of the most devastating neurological diseases; however, there no effective cure yet. The availability human induced pluripotent stem cells (iPSCs) provides unprecedented opportunities to understand pathogenic mechanism and identification new therapy for PD. Here a model system PD, including 2D iPSC-derived midbrain dopaminergic (mDA) neurons, 3D organoids (MOs) with cellular complexity, more advanced microphysiological systems (MPS) organoids, introduced. It believed that successful integrations applications iPSC, organoid, MPS technologies can bring insight on PD's pathogenesis will lead treatments this debilitating disease.

Language: Английский

---

Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer’s, Parkinson’s, and ALS

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 12613 - 12613

Published: Nov. 24, 2024

Neurodegenerative diseases, such as Alzheimer's, Parkinson's, ALS, and Huntington's, remain formidable challenges in medicine, with their relentless progression limited therapeutic options. These diseases arise from a web of molecular disturbances-misfolded proteins, chronic neuroinflammation, mitochondrial dysfunction, genetic mutations-that slowly dismantle neuronal integrity. Yet, recent scientific breakthroughs are opening new paths to intervene these once-intractable conditions. This review synthesizes the latest insights into underlying dynamics neurodegeneration, revealing how intertwined pathways drive course diseases. With an eye on most promising advances, we explore innovative therapies emerging cutting-edge research: nanotechnology-based drug delivery systems capable navigating blood-brain barrier, gene-editing tools like CRISPR designed correct harmful variants, stem cell strategies that not only replace lost neurons but foster neuroprotective environments. Pharmacogenomics is reshaping treatment personalization, enabling tailored align individual profiles, while diagnostics biomarkers ushering era early, precise disease detection. Furthermore, novel perspectives gut-brain axis sparking interest mounting evidence suggests microbiome modulation may play role reducing neuroinflammatory responses linked neurodegenerative progression. Taken together, advances signal shift toward comprehensive, personalized approach could transform care. By integrating techniques, this offers forward-looking perspective future where treatments aim just manage symptoms fundamentally alter progression, presenting renewed hope for improved patient outcomes.

Language: Английский

---